<div><div><p>[SINGAPORE] Home-grown biotech firm Mirxes will join the Hang Seng Composite Index on Sep 8, the startup announced on Saturday (Aug 23).</p><p>The Hang Seng Composite Index is a benchmark which covers about 95 per cent of the total market capitalisation of companies listed on the Hong Kong mainboard. It includes top Chinese companies such as Alibaba and Tencent. </p><p>“This significant milestone elevates the company’s market profile and enhances its strategic position within the Hong Kong and wider Asian capital markets,” said Mirxes. </p><div><div><div><div id="dfp-ad-imu1"></div></div></div></div><p>“Inclusion in the Hang Seng Composite Index is a powerful testament to Mirxes’ strong market position and solid performance since its listing on the Hong Kong Stock Exchange three months ago.” </p><p>Shares of Mirxes opened at HK$23.30 on May 23, and last traded at HK$45.82 on Friday. </p><p>Mirxes added that it expects its addition to the index to significantly increase the company’s visibility and trading liquidity, making its shares more attractive to a broader base of investors, including institutional funds and index-tracking exchange-traded funds.</p><div><div><div><div id="dfp-ad-midarticlespecial"></div></div></div></div><p>The inclusion may also enable the company’s shares to be traded among “a vast pool of investors in mainland China” through the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect schemes.</p><p>This would provide it with access to a crucial new source of capital to support its long-term growth and innovation pipeline, noted Mirxes.</p><p>Mirxes, founded in 2014, focuses on microRNA-based cancer detection. Its flagship product, GastroClear, is the world’s first molecular blood test approved for early detection of gastric cancer in high-risk populations.</p></div><div>MirxesBiotech</div><div><section><section><p>Share with us your feedback on BT's products and services</p><div>Feedback</div></section></section></div><div><div><div><div id="dfp-ad-imu2"></div></div></div></div></div>

02629

<p>總部位於新加坡的生物科技公司 Mirxes 將於 9 月 8 日加入恒生綜合指數，提升其在亞洲資本市場的市場形象和戰略地位。該指數包括阿里巴巴和騰訊等主要公司，Mirxes 預計將獲得更高的知名度和交易流動性，吸引更廣泛的投資者基礎。Mirxes 成立於 2014 年，專注於基於微小 RNA 的癌症檢測，其旗艦產品 GastroClear 是首個獲得批准的早期胃癌檢測分子血液測試</p>

總部位於新加坡的 Mirxes 將加入阿里巴巴和騰訊，成為恒生綜合指數的一部分